In Dec 2018, Biotecnol divested from it’s immuno-oncology pipeline and respective technologies (including Tb535H, and Trisoma®). Chiome will continue research and clinical development for Tb535H. In addition, Chiome will also continue generating new immune-oncology products using Biotecnol’s Trisoma® technology. Financial details were not disclosed. Biotecnol Limited, a spin-off of Biotecnol SA, a Portuguese pioneering company with a 20 year track record in development of Biologics, is an immuno-oncology company developing immune-function activating and immuno function modulation approaches using multi-specific antibody products based on its proprietary Tribody™ and Trisoma® technologies. Biotecnol has devised a novel way to further expand on the Tribody™ format and the Trisoma® platform to generate novel IP on a next generation of immune-response modulators called – Targeted T-cell Engaging Agonistic Response Modifiers or iChecks™. These products aim at improving tumor cell dependent T-cell activation. Due to its trispecific nature, the approach is expected to achieving a more localized immune activation and obtain less or no systemic toxicity with an increased therapeutic index. These are potentially safer and more effective drugs for highly-heterogeneous and highly-aggressive solid tumours. In 2017 the Cancer Research UK became shareholder in Biotecnol; Clinical research in oncology has evolved significantly over the last 5 years. Novel protocols using combination therapies of a variety of novel biological and traditional chemical agents have shown great promise in managing survival in cancer patients. Biotecnol’s strategy is to work with top cancer institutions in the immune-oncology field, such as CRUK, which will help the company to accelerate the development of cutting-edge therapeutic approaches to fight cancer, especially in solid tumours, an area which is in great demand for effective products.